Katherine Ansley, MD
Hematology & Oncology · Winston Salem, NCNPI 1780983908
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,606 of the $2,559 with a category attached, or 62.8%. Roche Products Limited accounts for 66.2% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2020 at $1,634 and has fallen 98.4% since, to $27 in 2024.
Across 11 payments — averaging $232.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Roche Products Limited$2K
- Hoffmann-la Roche Limited$795
- Pfizer$30
- Recordati_rare_diseases_inc.$27
- Gilead$12
Across 75 payments — averaging $3064.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$215K
- F. Hoffmann-la Roche AG$15K
What the payments were for
- Travel & lodging$1,60663%
- Food & beverage$92836%
- Education$251%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Roche Products Limited | 4 | $1,694 |
| Hoffmann-la Roche Limited | 3 | $795 |
| Pfizer | 2 | $30 |
| Recordati_rare_diseases_inc. | 1 | $27 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Non-Covered Product$2,332
How this compares
$2,559 in reported general payments places this provider in the 60th percentile of 358 hematology & oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 39 | $578,730 |
| KisqaliRibociclib Succinate | 41 | $565,867 |
| IbrancePalbociclib | 12 | $167,073 |
| EliquisApixaban | 18 | $18,148 |
| Anastrozole | 262 | $3,969 |
| Letrozole | 141 | $3,243 |
| Tamoxifen Citrate | 44 | $1,692 |
| Exemestane | 19 | $1,651 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 16 | $380 |
| Dexamethasone | 21 | $361 |
| Oxycodone Hcl | 16 | $349 |
| Gabapentin | 15 | $318 |
| Ondansetron OdtOndansetron | 20 | $308 |
| Klor-Con M20Potassium Chloride | 12 | $285 |
| Ondansetron Hcl | 29 | $223 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $30 | $185,22130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 358 hematology & oncology providers in North Carolina.
Other hematology & oncology in Winston Salem
- Angela AlistarWinston Salem$509K
- Ravi PaluriWinston Salem$314K
- Caio Max Rocha LimaWinston Salem$110K
- Timothy PardeeWinston Salem$68K
- Leon Bernal-MizrachiWinston Salem$62K
- Matthew WieduwiltWinston Salem$36K
- John McKayWinston Salem$22K
- Amit MehtaCary$4.3M
- Michael MorseDurham$2.6M
- Shelbi AtrashCharlotte$994K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.